Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations.
about
Idiopathic Inflammatory Myopathies: Clinical Approach and ManagementVitamin D receptor agonists: suitable candidates as novel therapeutic options in autoimmune inflammatory myopathyRisk factors for osteoporosis, falls and fractures in hereditary myopathies and sporadic inclusion body myositis - A cross sectional survey.Clinical features of idiopathic inflammatory polymyopathy in the Hungarian Vizsla.Prognostic factors for myositis-associated interstitial lung diseaseStatin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum".Toxoplasmic encephalitis during mycophenolate mofetil immunotherapy of neuromuscular disease.Multi-parametric MRI characterization of inflammation in murine skeletal muscle.Biologic predictors of clinical improvement in rituximab-treated refractory myositisDevelopment of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies.Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.Investigation into the cause of mortality in 49 cases of idiopathic inflammatory myopathy: A single center studyIncreased Expression of the NOD-like Receptor Family, Pyrin Domain Containing 3 Inflammasome in Dermatomyositis and Polymyositis is a Potential Contributor to Their Pathogenesis.Inflammatory myopathy as the initial presentation of cryoglobulinaemic vasculitisCase Report: Elevated CPK, an indicator of idiopathic inflammatory myopathy?Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.Corticosteroids in Myositis and Scleroderma.Current pharmacological treatment of idiopathic inflammatory myopathies.Amyopathic Dermatomyositis Associated with Histopathological Findings of Organizing Pneumonia and Pulmonary Vasculitis.Treatment of muscle weakness in neuromuscular disorders.Juvenile dermatomyositis: a tertiary center experience.Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.Adult dermatomyositis with bleeding ulcer in the pharynx.Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis.Clinico-serologic features of statin-induced necrotising autoimmune myopathy in a single-centre cohort.The top clinical trial opportunities in therapeutic apheresis and neurology.The roles of neutrophil serine proteinases in idiopathic inflammatory myopathies.
P2860
Q26744705-E7220D73-06D3-473C-BCE2-A7C50516E19EQ26849424-B0C24EDF-5817-4FA0-9225-A94CC13C4082Q30317527-856EB6EA-7E8B-4776-9E1A-C6D15C16FCD6Q30645348-43E493D6-178F-4F2A-8B3B-0680D516CE2CQ33721518-B378A04F-EADE-45EE-9056-F27B20FD7552Q34654243-68AEF32D-D393-4618-B6EE-7AC9B0E49EC4Q35023341-371B421C-15FD-449A-AB2B-F2519593B4C9Q35159099-BEE4892E-BC55-41D3-8B50-B96E0D6DD69BQ35779841-C36D485B-97FA-4613-81BA-64EF7192C5DDQ36335887-3957A74E-0008-404D-B910-6238332702E2Q36424500-6EF74A5B-E8B0-4805-91C1-7589F019A65AQ36639876-18D084DA-0818-4152-9536-DEF11813949BQ36856554-525D6F6F-B79C-4BA8-A4D7-A97E5E154B73Q36987016-E6A449A0-1C0A-4BBA-8B13-235381E38FB9Q37137104-1FDD2171-5256-40A1-8A3A-66F254C0CF16Q37368405-05DF2DB6-9136-4222-B830-DAE884934DDCQ37595787-B0EE5F0B-FCEB-4E6A-B8DB-B33646077FE9Q38649505-5EF79527-EA3C-43FE-8DE6-83D920B45227Q38680762-AE4F5A3D-401E-4075-A5A4-44173F7FD4FDQ38819614-67DC3005-8CA1-4439-BD8B-FF757D1871DAQ38845507-EB2F545B-8E31-4A74-9794-C9BDF5077A33Q39036962-34C4FADD-31DB-4E1A-B34B-77B4F057A324Q39160731-75A5D642-58D1-4839-BE8B-C6D5138B4B6CQ39604919-56412BC4-8D3E-479B-AC37-833A98B67AE2Q40186268-3EB5E6D7-89CA-453A-A600-8A6A5A0FBE40Q41626536-27237D7D-83A7-4324-B52B-DEF3AC90FE71Q47988184-24236A09-1599-48CD-B43C-9C488EA81F8DQ48894285-45B74CE7-3613-41C6-93FB-F5B7140323E6Q55457333-09BA005A-56A7-499A-AB6A-A6676237C742
P2860
Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Idiopathic inflammatory myopat ...... ate treatment recommendations.
@en
type
label
Idiopathic inflammatory myopat ...... ate treatment recommendations.
@en
prefLabel
Idiopathic inflammatory myopat ...... ate treatment recommendations.
@en
P1476
Idiopathic inflammatory myopat ...... ate treatment recommendations.
@en
P2093
Ann M Reed
Floranne C Ernste
P304
P356
10.1016/J.MAYOCP.2012.10.017
P407
P577
2013-01-01T00:00:00Z